心房細動市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別（薬理学的治療）、非薬理学的治療、最終用途別、地域別、競合別、2020-2030年

心房細動の世界市場は、2024年に225億4,000万米ドルと評価され、予測期間中にCAGR 7.19％で成長し、2030年には341億8,000万米ドルに達すると予測されています。

心房細動は、不規則でしばしば急速な心拍を特徴とする一般的な心臓不整脈であり、脳卒中、心不全、その他の心血管合併症のリスクを著しく増大させる。世界の罹患率の増加は、高齢化、肥満率の増加、ライフスタイルに起因する健康問題などの要因によるものです。この疾患は、ヘルスケアシステムにとって臨床的にも経済的にも大きな負担となっています。COVID-19の大流行は、心臓手術を減らす一方で、遠隔医療や遠隔モニタリングのようなデジタルヘルスケアアプローチの重要性を強調しました。その結果、効果的な心房細動管理に対する需要は高まり続け、治療と診断の進歩を促進しています。

市場促進要因

高齢化人口の増加が世界の心房細動市場を牽引

主な市場課題

認知度の不足

主要市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の心房細動市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別（薬物治療（抗不整脈薬）、非薬物治療（カテーテルアブレーション、メイズ手術、電気的除細動））
  • 用途別（病院、専門クリニック、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の心房細動市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の心房細動市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の心房細動市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の心房細動市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの心房細動市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品開発
• 最近の動向

第13章 世界の心房細動市場：SWOT分析

第14章 競合情勢

• Parexel International Corporation
• AtriCure Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Bristol-Myers Squibb Corporation
• Cardio Focus Inc.
• Sanofi Aventis
• Biosense Webster Inc.
• Endoscopic Technologies Inc.
• Abbott Laboratories
• Johnsons & Johnson Services, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Atrial Fibrillation Market was valued at USD 22.54 Billion in 2024 and is projected to reach USD 34.18 Billion by 2030, growing at a CAGR of 7.19% during the forecast period. Atrial fibrillation, a prevalent cardiac arrhythmia marked by irregular and often rapid heartbeats, significantly increases the risk of stroke, heart failure, and other cardiovascular complications. Its growing incidence globally is attributed to factors such as the aging population, increasing obesity rates, and lifestyle-induced health issues. This condition poses a considerable clinical and financial burden on healthcare systems. The COVID-19 pandemic, while reducing cardiac surgeries, emphasized the importance of digital healthcare approaches like telemedicine and remote monitoring-trends that are expected to persist and support market growth. As a result, the demand for effective atrial fibrillation management continues to rise, driving advancements in treatment and diagnosis.

Key Market Drivers

Increasing Aging Population is Driving the Global Atrial Fibrillation Market

The growing global aging population is a major factor fueling the expansion of the atrial fibrillation market. Older individuals are more susceptible to this condition due to age-related health risks such as hypertension, obesity, and diabetes. As the proportion of elderly people rises, so does the prevalence of atrial fibrillation. According to the American Heart Association, the likelihood of developing atrial fibrillation doubles with every decade after age 50. Additionally, the World Health Organization reports that by 2030, one in six people globally will be over 60, with the number expected to reach 2.1 billion by 2050. This demographic trend is significantly influencing the demand for atrial fibrillation therapies and solutions.

Key Market Challenges

Lack of awareness

A major hurdle in combating atrial fibrillation globally is the widespread lack of awareness. Despite being common, the condition often goes undiagnosed or is insufficiently treated. This is largely due to limited public understanding of its symptoms and potential severity, resulting in delayed diagnoses and inadequate interventions. The insufficient awareness among both patients and healthcare providers continues to impede efforts to effectively manage and reduce the burden of atrial fibrillation worldwide.

Key Market Trends

Technological Advancements

Technological innovations are transforming the diagnosis and management of atrial fibrillation, leading to improved patient outcomes and more efficient healthcare delivery. As the most common form of cardiac arrhythmia, atrial fibrillation can result in serious complications, making early and accurate detection critical. Advanced tools and procedures, including minimally invasive surgical techniques and remote monitoring solutions, are gaining prominence. These developments cater to growing demand for safer, more precise treatment methods and are playing a pivotal role in expanding the global atrial fibrillation market.

Key Market Players

• Parexel International Corporation
• AtriCure Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Bristol- Myers Squibb Corporation
• Cardio Focus Inc.
• Sanofi Aventis
• Biosense Webster Inc.
• Endoscopic Technologies Inc.
• Abbott Laboratories
• Johnsons & Johnson Services, Inc.

Report Scope:

In this report, the Global Atrial Fibrillation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atrial Fibrillation Market, By Treatment Type:

• Pharmacological Treatment
• Non-Pharmacological Treatment

Atrial Fibrillation Market, By End Use:

• Hospital
• Specialty Clinics
• Others

Atrial Fibrillation Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Atrial Fibrillation Market.

Available Customizations:

Global Atrial Fibrillation market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Atrial Fibrillation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Pharmacological Treatment (Anti-arrhythmic Drugs), Non-Pharmacological Treatment(Catheter Ablation, Maze Surgery, Electric Cardioversion)
  • 5.2.2. By End-use (Hospital, Specialty Clinics, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Atrial Fibrillation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By End-Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Atrial Fibrillation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By End-Use
  • 6.3.2. Canada Atrial Fibrillation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By End-Use
  • 6.3.3. Mexico Atrial Fibrillation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By End-Use

7. Europe Atrial Fibrillation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By End-Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Atrial Fibrillation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By End-Use
  • 7.3.2. United Kingdom Atrial Fibrillation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By End-Use
  • 7.3.3. Italy Atrial Fibrillation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By End-Use
  • 7.3.4. France Atrial Fibrillation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By End-Use
  • 7.3.5. Spain Atrial Fibrillation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By End-Use

8. Asia-Pacific Atrial Fibrillation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By End-Use
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Atrial Fibrillation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By End-Use
  • 8.3.2. India Atrial Fibrillation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By End-Use
  • 8.3.3. Japan Atrial Fibrillation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By End-Use
  • 8.3.4. South Korea Atrial Fibrillation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By End-Use
  • 8.3.5. Australia Atrial Fibrillation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By End-Use

9. South America Atrial Fibrillation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By End-Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Atrial Fibrillation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By End-Use
  • 9.3.2. Argentina Atrial Fibrillation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By End-Use
  • 9.3.3. Colombia Atrial Fibrillation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By End-Use

10. Middle East and Africa Atrial Fibrillation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By End-Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Atrial Fibrillation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By End-Use
  • 10.3.2. Saudi Arabia Atrial Fibrillation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By End-Use
  • 10.3.3. UAE Atrial Fibrillation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Product Development
• 12.3. Recent Developments

13. Global Atrial Fibrillation Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Parexel International Corporation
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. AtriCure Inc.
• 14.3. Boehringer Ingelheim GmbH
• 14.4. Boston Scientific Corporation
• 14.5. Bristol- Myers Squibb Corporation
• 14.6. Cardio Focus Inc.
• 14.7. Sanofi Aventis
• 14.8. Biosense Webster Inc.
• 14.9. Endoscopic Technologies Inc.
• 14.10. Abbott Laboratories
• 14.11. Johnsons & Johnson Services, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer